Vanda Pharmaceuticals Inc.VNDANASDAQ
LOADING
|||
Year-over-year research & development expense growth
| Period | Value |
|---|---|
| Q3 2025 | 2.61% |
| Q2 2025 | -38.42% |
| Q1 2025 | 80.00% |
| Q4 2024 | 18.26% |
| Q3 2024 | 0.69% |
| Q2 2024 | -21.24% |
| Q1 2024 | -13.09% |
| Q4 2023 | 46.62% |
| Q3 2023 | -0.28% |
| Q2 2023 | -13.46% |
| Q1 2023 | 4.24% |
| Q4 2022 | -25.76% |
| Q3 2022 | 15.67% |
| Q2 2022 | 2.48% |
| Q1 2022 | 8.47% |
| Q4 2021 | -1.64% |
| Q3 2021 | -2.94% |
| Q2 2021 | 25.52% |
| Q1 2021 | 8.63% |
| Q4 2020 | 20.74% |
| Q3 2020 | -4.69% |
| Q2 2020 | -16.90% |
| Q1 2020 | 18.76% |
| Q4 2019 | 15.22% |
| Q3 2019 | 3.63% |
| Q2 2019 | -17.53% |
| Q1 2019 | 2.75% |
| Q4 2018 | 13.45% |
| Q3 2018 | 15.45% |
| Q2 2018 | 4.78% |
| Q1 2018 | -7.27% |
| Q4 2017 | -0.24% |
| Q3 2017 | 33.08% |
| Q2 2017 | -27.62% |
| Q1 2017 | 38.78% |
| Q4 2016 | 4.39% |
| Q3 2016 | 8.87% |
| Q2 2016 | -11.23% |
| Q1 2016 | -13.71% |
| Q4 2015 | -12.30% |